X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ATB-346 (otenaproxesul) is a novel hydrogen sulfide-releasing, nonsteroidal anti-inflammatory drug, which is being evaluated for the treatment of acute pain.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
ATB-346 (otenaproxesul) ia a COX-2 inhibitor which is in clinical development as a safer alternative to opioids and today’s NSAIDs that releases hydrogen sulfide, for acute pain.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The new formulation’s benefits include rapid dissolution mechanics, accelerating otenaproxesul’s (ATB-346) onset of action, a key benchmark for acute pain medications; and enhanced bioavailability, enabling a significant dose reduction compared to its current formulation.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
ATB-346 (otenaproxesul) is novel nonsteroidal anti-inflammatory drug (“NSAID”) that releases hydrogen sulfide. Antibe is leveraging the drug’s remarkable potency, gastrointestinal (“GI”) protection and overall safety profile for use in acute pain indications.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
The AME study had enrolled a total of 42 subjects on either a 75 mg or 100 mg daily dose of otenaproxesul, of whom 35 had completed the 28-day drug administration period, with seven subjects having been administered the drug for 21 days.
Lead Product(s): Otenaproxesul
Therapeutic Area: Musculoskeletal Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.
Lead Product(s): Otenaproxesul
Therapeutic Area: Musculoskeletal Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Veristat
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan, representing approximately 10% of the worldwide pharma market.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nuance Pharma
Deal Size: $100.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement February 09, 2021
Details:
The net proceeds of the Offering will be used to fund activities required for large market partnering and in support of the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company’s pipeline including ATB-352.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 09, 2020
Details:
Conference will focus on the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
The 150 mg dose of ATB-346, although not powered for statistical significance, demonstrated more potency than expected and the lowest effective dose is still to be established.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Antibe's partner, Veristat, was able to complete the Phase 2B dose-ranging, efficacy study for ATB-346 and capture all patient data without compromising the size and integrity of the study.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis (OA) pain compared to placebo in 360 patients.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
